HGH Production Through Sermorelin Acetate Injections

Human Growth Hormone (HGH) is a hormone proven to decrease injury recovery time. It’s secreted by the pituitary gland, and it’s completely harmless when produced this way. As we age, we may experience a decrease in HGH production, causing injuries to linger on for weeks or even months. Fortunately, McQuinn Naturopathic now offers Sermorelin Acetate injections to counteract the effects of aging.

The True Cause of Aging
Growth Hormone Deficiency (GHD) is a natural part of growing older, but it can result in many aches and pains which make life far less enjoyable. Naturally stimulating the endocrine system to produce more HGH can alleviate many symptoms of aging, resulting in a more vibrant youthful exuberance.

Treating the Real Issue
The decrease in HGH in older adults is caused by a deficiency of Growth Hormone Releasing Hormone (GH-RH). Sermrelin Acetate is a synthetic form of this hormone, which signals the body to produce its own HGH. This is a much safer alternative to introducing HGH directly into the body. This is the method sometimes used by professional athletes. HGH is best utilized by the body when it produced within the endocrine organs. Injuries will heal faster, and the more responsive, cognitive thinking associated with being young.
McQuinn Naturopathic Family Practice is well known for the use of holistic treatments, and this latest treatment only strengthens their repertories. Sermorelin Acetate injections can help older adults get back to a regular life, and help athletes decrease injury recovery time. Contact us for more information or to schedule an appointment.

For more information on HGH Production Through Sermorelin Acetate Injections, and to schedule a consultation today, contact McQuinn Naturopathic at (425)905-2487.

Sermorelin therapy is available via prescription only.

Sermorelin Therapy May Provide the Following Benefits:

  • Development of lean body mass
  • Body fat reduction
  • Increases energy and vitality
  • Improves strength and endurance
  • Accelerates healing from wounds or surgery
  • Cardiovascular and immune function
  • IGF-1 production
  • Sleep quality
  • Bone density
  • Increase skin density and collagen production
  • Protein synthesis
  • Homeostasis
  • Pancreatic and Liver function
  • Increase testosterone

 

Sermorelin Therapy Q & A

Q: What is Sermorelin?
A: Sermorelin is a form of growth hormone releasing factor (GRF) that contains only the first 29 amino acids. The GRF that is produced by neurosecretory neurons in the brain contains 44 amino acids. In the 1970’s, Nobel Laureates, R. Guilleman and A. Shalley found that only the first 29 amino acids are responsible for stimulating pituitary production and secretion of hGH. Therefore, the chemical name for Sermorelin is
GRH 1-29 NH 2.

Sermorelin is a prescription drug, compounded by U.S. pharmacies pursuant to a physician’s prescription and patient self-injected subcutaneously. It stimulates the pituitary gland to naturally produce increased amounts of growth hormone. Sermorelin is a truncated analog of a growth hormone releasing factor (GRF 1-44) that is naturally produced by the brain to stimulate pituitary production of HGH. The increased
volume of HGH produced by the pituitary gland causes an increase in the production of Insulin-Like Growth Factor-1 (IGF-1) by the liver and results in the benefits of treatment provided to the adult patient.

Q: Is Sermorelin therapy the same as HGH therapy?
A: No, Sermorelin is a growth hormone secretagogue, which means that it stimulates the pituitary gland to produce and secrete growth hormone. Sermorelin is a small peptide containing only 29 amino acids, whereas HGH (human growth hormone) is a much larger molecule containing 191 amino acids.

Sermorelin Therapy Q & A Continued >>

Peptide Differences

GHRP-2

Growth-Hormone-Releasing-Peptide-Two (GHRP-2) is a synthetic ghrelin analogue. It causes the release of endogenous (internal) Growth Hormone (GH) from somatotropes in the anterior pituitary gland. It works synergistically with GHRHs and lacks the lipogenic properties (fat creation/storage) of ghrelin. GHRP-2 excites the hypothalamus and causes a high release of GH, which tapers back to baseline by the third hour post admin. This pulse closely represents that of the natural pulse of the human body giving it an advantage over synthetic GH use.

Benefits and Potential of GHRP-2

Similar to Ipamorelin, GHRP-2 has great benefit and potential in athletes and wellness. GHRP-2 has been studied and shown to be effective in treating age-related GH decline when used in combination with a GHRH such as CJC-1295. GHRP-2 when use with an equal dose of a GHRH creates a 3-hour pulse of GH that is double the amplitude of 8IU of synthetic GH. This makes it a more effective, healthier substitute to synthetic Growth Hormone with the added safety and lower cost benefits.

GHRP-6

Growth-Hormone-Releasing-Peptide-6 (GHRP-6) is a Growth Hormone (GH) secretagogue and ghrelin mimetic.

The peptide GHRP-6 works similarly to GHRP-2 and Ipamorelin, however it induces hunger consistently in mammals. It also does have some lipogenic properties that are dependent on the status on insulin and glucose. GHRP-6 may cause weight and adipose tissue gain if insulin is present. Our physicians recommend not eating for 30 minutes post injection.

Benefits and Potential of GHRP-6
Again, similar to GHRP-2 and Ipamorelin, GHRP-6 has many benefits and uses. Due to the increased GH release, the following benefits may be observed:

  • Increased Energy
  • Improved Sleep
  • Increased Lean Body Mass
  • Decreased Body Fat
  • Increased Collagen Production
  • Increased Healing Capability

Ipamorelin

Ipamorelin or NNC 26-0161, a polypeptide hormone, is a growth hormone secretagogue and ghrelin mimetic and analog developed by Novo Nordisk[3]. Ipamorelin belongs to the most recent generation of GHRPs from the mid 1990s and causes significant release of growth hormone by itself, due both to its suppression of somatostatin (an antagonist to GHRH) and stimulation of release of GH from the anterior pituitary, similar to GHRP-2 and GHRP-6 which are compounds from the same class (growth hormone releasing peptides).[1] The cells that produce and release GH are known as somatotropes.[2] Like GHRP-2, ipamorelin does not have ghrelin’s lipogenic properties. Like GHRP-2 and unlike GHRP-6 ipamorelin never induces hunger in mammals. Ipamorelin acts synergistically when applied during a native GHRH (growth-hormone releasing hormone) pulse or when co-administered with GHRH or a GHRH analog such as Sermorelin or GRF 1-29 (growth releasing factor, aminos 1-29).[1] The synergy comes both due to the suppression of somatostatin and the fact that ipamorelin increases GH release per-somatotrope, while GHRH increases the number of somatotropes releasing GH.[1,2] There is also a secondary effect of neuronal excitation in the hypothalamus caused by ipamorelin, which lasts for approximately 3 hours after application, similar to GHRP-2 and GHRP-6.

Ipamorelin has a unique property among the GHRP class of peptides. That property is known as selectiveness. WhereasGHRP-6 and GHRP-2 cause a release and increase in cortisol and prolactin levels, ipamorelin only selectively releases GH at any dose. Further, a mega-dose of ipamorelin results in a concomitant mega-release of GH (up to the entire amount present in the pituitary), whereas GHRP-2 and GHRP-6 have limits of approximately 1mcg/kg in humans for their maximal GH release.[4,5]

Raun et al demonstrated the selectiveness of ipamorelin for GH release only in a study:
The development and pharmacology of a new potent growth hormone (GH) secretagogue, ipamorelin, is described. Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2), which displays high GH releasing potency and efficacy in vitro and in vivo. As an outcome of a major chemistry programme, ipamorelin was identified within a series of compounds lacking the central dipeptide Ala-Trp of growth hormone-releasing peptide (GHRP)-1. In vitro, ipamorelin released GH from primary rat pituitary cells with a potency and efficacy similar to GHRP-6 (ECs) = 1.3+/-0.4nmol/l and Emax = 85+/-5% vs 2.2+/-0.3nmol/l and 100%). A pharmacological profiling using GHRP and growth hormone-releasing hormone (GHRH) antagonists clearly demonstrated that ipamorelin, like GHRP-6, stimulates GH release via a GHRP-like receptor. In pentobarbital anaesthetised rats, ipamorelin released GH with a potency and efficacy comparable to GHRP-6 (ED50 = 80+/-42nmol/kg and Emax = 1545+/-250ng GH/ml vs 115+/-36nmol/kg and 1167+/-120ng GH/ml). In conscious swine, ipamorelin released GH with an ED50 = 2.3+/-0.03 nmol/kg and an Emax = 65+/-0.2 ng GH/ml plasma. Again, this was very similar to GHRP-6 (ED50 = 3.9+/-1.4 nmol/kg and Emax = 74+/-7ng GH/ml plasma). GHRP-2 displayed higher potency but lower efficacy (ED50 = 0.6 nmol/kg and Emax = 56+/-6 ng GH/ml plasma). The specificity for GH release was studied in swine. None of the GH secretagogues tested affected FSH, LH, PRL or TSH plasma levels. Administration of both GHRP-6 and GHRP-2 resulted in increased plasma levels of ACTH and cortisol. Very surprisingly, ipamorelin did not release ACTH or cortisol in levels significantly different from those observed following GHRH stimulation. This lack of effect on ACTH and cortisol plasma levels was evident even at doses more than 200-fold higher than the ED50 for GH release. In conclusion, ipamorelin is the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH. The specificity of ipamorelin makes this compound a very interesting candidate for future clinical development.[3]

Cititations:
[1] Bowers CY, Momany F, Reynolds GA. In vitro and in vivo activity of a small synthetic peptide with potent GH releasing activity. 64th Annual Meeting of the Endocrine Society, San Francisco, 1982, p. 205.
[2]Bowers CY, Momany F, Reynolds GA, Sartor O. Multiple receptors mediate GH release. 7th International Congress of Endocrinology, Quebec, Canada, 1984, p. 464.
[3] Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61.
[4] Brosnan-Cook, M. et al. (1998) Iontophoretic delivery of ipamorelin, a growth hormone secretagogue. Proceedings of 80th Annual Meeting Endocrine Society, New Orleans, USA. Abstract Pp1-186.
[5] Jogarao V S Gobburu; Henrik Agerso; William J Jusko . Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide in Human Volunteers. Lars Ynddal Pharmaceutical Research: Sep 1999; 16, 9; ProQuest Nursing & Allied Health Source p. 1412.

Before using Sermorelin Acetate:

Some medical conditions may interact with Sermorelin Acetate. Tell your doctor or
pharmacist if you have any medical conditions, especially if any of the following apply to you:

  • if you are pregnant, planning to become pregnant, or are breast-feeding
  •  if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement
  • if you have allergies to medicines, foods, or other substances
  • if you have a head or brain injury or disease

Some MEDICINES MAY INTERACT with Sermorelin Acetate. Tell your health care provider
if you are taking any other medicines, especially any of the following:

  • Cyclooxygenase inhibitors (eg, aspirin, indomethacin), glucocorticoids (eg,
    prednisone), insulin, medicines that lower thyroid levels (eg, propylthiouracil), muscarinic antagonists (eg, atropine), or somatostatin-containing medicines or medicines that release somatostatin (eg, clonidine, levodopa) because the effectiveness of Sermorelin Acetate to diagnose a disorder may be decreased
  • This may not be a complete list of all interactions that may occur. Ask your health care provider if Sermorelin Acetate may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

Important safety information:

  • LAB TESTS, including growth hormone levels, may be performed to monitor your
    progress or to check for side effects. Be sure to keep all doctor and lab appointments.
  • PREGNANCY and BREAST-FEEDING: If you become pregnant while taking
    Sermorelin Acetate, discuss with your doctor the benefits and risks of using Sermorelin Acetate during pregnancy. It is unknown if Sermorelin Acetate is excreted in breast milk. If you are or will be breast-feeding while you are using Sermorelin Acetate, check with your doctor or pharmacist to discuss the risks to your baby.

Possible side effects of Sermorelin Acetate:

All medicines may cause side effects, but many people have no, or minor, side effects.
Check with your doctor if any of these most COMMON side effects persist or become
bothersome:

Facial flushing; headache; nausea; pain, redness, or swelling at injection site; paleness;
strange taste in mouth; vomiting.

Seek medical attention right away if any of these SEVERE side effects occur: Severe
allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue).

Additional Resources and Product Information

Sermorelin with Peptides >>

Sermorelin vs rhGH in GHRT 1: A New Paradigm for Treating Adult Onset Growth Hormone Deficiency >>

For more information on HGH Production Through Sermorelin Acetate Injections, and to schedule a consultation today, contact McQuinn Naturopathic at (425)905-2487.